Transmission of Clostridium difficile During Hospitalization for Allogeneic Stem Cell Transplant

被引:21
|
作者
Kamboj, Mini [1 ,2 ,3 ]
Sheahan, Anna [1 ]
Sun, Janet [1 ]
Taur, Ying [2 ,3 ]
Robilotti, Elizabeth [1 ,2 ,3 ]
Babady, Esther [4 ]
Papanicolaou, Genovefa [2 ,3 ]
Jakubowski, Ann [3 ,5 ]
Pamer, Eric [2 ,3 ]
Sepkowitz, Kent [1 ,2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Control, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY 10021 USA
[3] Weill Cornell Med Coll, Dept Med, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Clin Labs, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Bone Marrow Transplant Serv, New York, NY 10021 USA
来源
关键词
TERM-CARE FACILITY; RISK-FACTORS; ASYMPTOMATIC CARRIERS; INFECTION; EPIDEMIOLOGY; RECIPIENTS; STRAIN; SURVEILLANCE; OUTBREAK; OUTCOMES;
D O I
10.1017/ice.2015.237
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE To determine the role of unit-based transmission that accounts for cases of early Clostridium difficile infection (CDI) during hospitalization for allogeneic stem cell transplant. SETTING Stem cell transplant unit at a tertiary care cancer center. METHODS Serially collected stool from patients admitted for transplant was screened for toxigenic C. difficile through the hospital stay and genotyping was performed by multilocus sequence typing. In addition, isolates retrieved from cases of CDI that occurred in other patients hospitalized on the same unit were similarly characterized. Transmission links were established by time-space clustering of cases and carriers of shared toxigenic C. difficile strains. RESULTS During the 27-month period, 1,099 samples from 264 patients were screened, 69 of which had evidence of toxigenic C. difficile; 52 patients developed CDI and 17 were nonsymptomatic carriers. For the 52 cases, 41 had evidence of toxigenic C. difficile on the first study sample obtained within a week of admission, among which 22 were positive within the first 48 hours. A total of 24 sequence types were isolated from this group; 1 patient had infection with the NAP1 strain. A total of 11 patients had microbiologic evidence of acquisition; donor source could be established in half of these cases. CONCLUSIONS Most cases of CDI after stem cell transplant represent delayed onset disease in nonsymptomatic carriers. Transmission on stem cell transplant unit was confirmed in 19% of early CDI cases in our cohort with a probable donor source established in half of the cases. Infect. Control Hosp. Epidemiol. 2015;37(1):8-15
引用
收藏
页码:8 / 15
页数:8
相关论文
共 50 条
  • [1] Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant
    Fusco, Brendon
    Tomita-Barber, Jasmine
    Mazzaferro, Natale
    Tyno, Anne
    Mcentee, Nicole
    Greenberg, Patricia
    Strair, Roger
    Schaar, Dale
    Cooper, Dennis
    TRANSPLANT INFECTIOUS DISEASE, 2025,
  • [2] Early Clostridium difficile Infection during Allogeneic Hematopoietic Stem Cell Transplantation
    Kinnebrew, Melissa A.
    Lee, Yeon Joo
    Jenq, Robert R.
    Lipuma, Lauren
    Littmann, Eric R.
    Gobourne, Asia
    No, Daniel
    van den Brink, Marcel
    Pamer, Eric G.
    Taur, Ying
    PLOS ONE, 2014, 9 (03):
  • [3] Recurrence of Clostridium difficile infection after total colectomy in an allogeneic stem cell transplant patient
    Chang, K.
    Kreuziger, L. M. B.
    Angell, K.
    Young, J-A
    Ustun, C.
    BONE MARROW TRANSPLANTATION, 2012, 47 (04) : 610 - 611
  • [4] Recurrence of Clostridium difficile infection after total colectomy in an allogeneic stem cell transplant patient
    K Chang
    L M B Kreuziger
    K Angell
    J-A Young
    C Ustun
    Bone Marrow Transplantation, 2012, 47 : 610 - 611
  • [5] Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient
    Neemann, K.
    Eichele, D. D.
    Smith, P. W.
    Bociek, R.
    Akhtari, M.
    Freifeld, A.
    TRANSPLANT INFECTIOUS DISEASE, 2012, 14 (06) : E161 - E165
  • [6] Risk Factors for Recurrent Clostridium Difficile Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Mani, Shylaja
    Rybicki, Lisa
    Jagadeesh, Deepa
    Mossad, Sherif B.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S240 - S241
  • [7] Recommendations for controlling nosocomial transmission of Clostridium difficile in a haematopoietic stem cell transplant unit
    Claisse, JP
    Tabani, K
    Rouveau, M
    Pinto, FO
    Socié, G
    BONE MARROW TRANSPLANTATION, 2006, 37 : S293 - S294
  • [8] Surveillance cultures for Clostridium difficile in allogeneic haematopoietic stem cell transplantation
    Ferrant, A.
    Vekemans, M. -C.
    Servaty, A. -M.
    Delmee, M.
    Poire, X.
    Van Den Neste, E.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S213 - S213
  • [9] Does Oral Vancomycin Prophylaxis for Clostridium Difficile Infection Improve Allogeneic Hematopoietic Stem Cell Transplant Outcomes?
    Pereiras, Maribel A.
    Urnoski, Eric
    Wynd, Michael
    Cicogna, Cristina
    Sebti, Rani
    Mccoy, Dorothy
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S389 - S389
  • [10] Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Ganetsky, Alex
    Han, Jennifer H.
    Hughes, Mitchell E.
    Babushok, Daria V.
    Frey, Noelle V.
    Gill, Saar I.
    Hexner, Elizabeth
    Loren, Alison Wakoff
    Luger, Selina
    Mangan, James K.
    Smith, Jacqueline
    Stadtmauer, Edward A.
    Freyer, Craig W.
    Gilmar, Cheryl
    Porter, David L.
    BLOOD, 2016, 128 (22)